P.6.044 Catatonia relief with zolpidem: An open study

Rasele, C.; Thomas, P.; Maron, Michel; Mastain, B.; Guesdon, I.; Cottencin, Olivier; Vaïva, Guillaume; Goudemand, M.

doi:10.1016/s0924-977x(97)88920-1

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, Mastain and colleagues were the first to report a dramatic durable improvement of catatonia, resistant to ECT and benzodiazepines, with zolpidem in a 56-year-old woman that was in a catatonic state secondary to a subcortical stroke ( 98 ). Two years later, the same group presented an open study with zolpidem in seven catatonic patients, observing remission of catatonic symptoms in five of them within 15–30 min after ingestion, lasting 2–5 h ( 99 ). They observed these therapeutic effects at a plasma concentration between 80 and 130 ng/L.…”

Section: Treatment Of Catatoniamentioning

confidence: 99%

A Clinical Review of the Treatment of Catatonia

Sienaert¹,

Dhossche²,

Vancampfort³

et al. 2014

Front. Psychiatry

243

312

View full text Add to dashboard Cite

Catatonia is a severe motor syndrome with an estimated prevalence among psychiatric inpatients of about 10%. At times, it is life-threatening especially in its malignant form when complicated by fever and autonomic disturbances. Catatonia can accompany many different psychiatric illnesses and somatic diseases. In order to recognize the catatonic syndrome, apart from thorough and repeated observation, a clinical examination is needed. A screening instrument, such as the Bush-Francis Catatonia Rating Scale, can guide the clinician through the neuropsychiatric examination. Although severe and life-threatening, catatonia has a good prognosis. Research on the treatment of catatonia is scarce, but there is overwhelming clinical evidence of the efficacy of benzodiazepines, such as lorazepam, and electroconvulsive therapy.

show abstract

Section: Treatment Of Catatoniamentioning

confidence: 99%

A Clinical Review of the Treatment of Catatonia

Sienaert¹,

Dhossche²,

Vancampfort³

et al. 2014

Front. Psychiatry

243

312

View full text Add to dashboard Cite

show abstract

“…Zolpidem can be used as an alternative to lorazepam, as shown in a series of case reports and small open studies from a French research-group (Mastain et al, 1995;Rascle et al, 1997;Thomas et al, 1997). This beneficial response to zolpidem was confirmed by others (Peglow et al, 2013;Hlal et al, 2014).…”

Section: Zolpidemmentioning

confidence: 87%

The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia

Sienaert

Harten

Rhebergen³

2019

Handbook of Clinical Neurology

View full text Add to dashboard Cite

“…Among the drugs with this mechanism of action, zolpidem has found widespread use, which was first investigated by Mastain et al in 1995. However, its effectiveness is related to the need to monitor the therapeutic concentration in blood serum, ranging between 80 and 130 ng/mL [ 37 ]. The same authors described in the Lancet cases of recurrence of symptoms after the concentration dropped below 90 ng/mL [ 38 ].…”

Section: Treatment Of Catatoniamentioning

confidence: 99%

Paralyzed by Fear?—A Case Report in the Context of Narrative Review on Catatonia

Badura-Brzoza

Główczyński

Błachut

2022

IJERPH

View full text Add to dashboard Cite

In ICD-11, catatonia is a complex syndrome that includes psychomotor disorders (negativity, catalepsy, wax flexibility, mutism, automatism, mannerisms, or echolalia) and volitional processes affect modulation and action planning, which leads to hypofunctional, hyperfunctional, or parafunctional motor action. This is a very important clue that this state can be associated with both mental and somatic diseases. In order to create a narrative review, authors analyzed the diagnostic criteria of ICD-10 and ICD-11 and searched the PubMed medical base for articles on the diagnosis and different approaches to the treatment of catatonia. The treatment of catatonia is not standardized. It is based on the use of benzodiazepines, GABAa receptor antagonists, NMDA receptor antagonists, D2 receptor antagonist, and electroconvulsive therapy (ECT). The authors also would like to present the case of a patient in whom the diagnosis of catatonia was not so clear according to the diagnostic criteria, emphasizing the importance of the key diagnosis for the patient’s recovery. The authors would also like to point out that the topic of catatonia should be of interest not only to psychiatrists, but also to doctors of other specialties, who may encounter cases of catatonia complicating somatic states in hospital wards.

show abstract

P.6.044 Catatonia relief with zolpidem: An open study

Cited by 5 publications

References 0 publications

A Clinical Review of the Treatment of Catatonia

A Clinical Review of the Treatment of Catatonia

The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia

Paralyzed by Fear?—A Case Report in the Context of Narrative Review on Catatonia

Contact Info

Product

Resources

About